Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Bloor

Showing results (1-10 of 29) with videos related to

Pageof 3
Sort By:
Enzyme and Microbial Technology|January 1, 1991
Elucidation and optimization of the medium constituents controlling antibiotic production by the cyanobacterium Nostoc muscorumS Bloor, R R England
Journal of Virology|April 29, 1998
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitroP R Harrigan, S Bloor, B A Larder
Journal of Medical Virology|May 1, 1994
Development of a rapid quantitative assay for HIV-1 plasma infectious viraemia-culture-PCR (CPID)K Ariyoshi, S Bloor, P D Bieniasz, et al.
Gut|August 21, 2001
Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virusK M Walsh, T Woodall, P Lamy, et al.
Journal of Virology|May 30, 1998
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidineS D Kemp, C Shi, S Bloor, et al.
Angiogenesis|October 1, 2003
An in vitro model of angiogenesis: basic featuresE T Bishop, G T Bell, S Bloor, et al.
Journal of Virology|September 1, 1996
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibilityP R Harrigan, I Kinghorn, S Bloor, et al.
The Journal of Infectious Diseases|March 18, 2000
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative GroupP R Harrigan, C Stone, P Griffin, et al.
AIDS (London, England)|June 1, 1993
Variable relationship between proviral DNA load and infectious virus titre in the peripheral blood mononuclear cells of HIV-1-infected individualsP D Bieniasz, K Ariyoshi, M A Bourelly, et al.
The Journal of Infectious Diseases|November 22, 2000
Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasmaM A Poles, J Elliott, J Vingerhoets, et al.
Pageof 3

Showing results (1-10 of 29) with videos related to

Sort By:
Pageof 3
Enzyme and Microbial Technology|January 1, 1991
Elucidation and optimization of the medium constituents controlling antibiotic production by the cyanobacterium Nostoc muscorumS Bloor, R R England
Journal of Virology|April 29, 1998
Relative replicative fitness of zidovudine-resistant human immunodeficiency virus type 1 isolates in vitroP R Harrigan, S Bloor, B A Larder
Journal of Medical Virology|May 1, 1994
Development of a rapid quantitative assay for HIV-1 plasma infectious viraemia-culture-PCR (CPID)K Ariyoshi, S Bloor, P D Bieniasz, et al.
Gut|August 21, 2001
Successful treatment with adefovir dipivoxil in a patient with fibrosing cholestatic hepatitis and lamivudine resistant hepatitis B virusK M Walsh, T Woodall, P Lamy, et al.
Journal of Virology|May 30, 1998
A novel polymorphism at codon 333 of human immunodeficiency virus type 1 reverse transcriptase can facilitate dual resistance to zidovudine and L-2',3'-dideoxy-3'-thiacytidineS D Kemp, C Shi, S Bloor, et al.
Angiogenesis|October 1, 2003
An in vitro model of angiogenesis: basic featuresE T Bishop, G T Bell, S Bloor, et al.
Journal of Virology|September 1, 1996
Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibilityP R Harrigan, I Kinghorn, S Bloor, et al.
The Journal of Infectious Diseases|March 18, 2000
Resistance profile of the human immunodeficiency virus type 1 reverse transcriptase inhibitor abacavir (1592U89) after monotherapy and combination therapy. CNA2001 Investigative GroupP R Harrigan, C Stone, P Griffin, et al.
AIDS (London, England)|June 1, 1993
Variable relationship between proviral DNA load and infectious virus titre in the peripheral blood mononuclear cells of HIV-1-infected individualsP D Bieniasz, K Ariyoshi, M A Bourelly, et al.
The Journal of Infectious Diseases|November 22, 2000
Despite high concordance, distinct mutational and phenotypic drug resistance profiles in human immunodeficiency virus type 1 RNA are observed in gastrointestinal mucosal biopsy specimens and peripheral blood mononuclear cells compared with plasmaM A Poles, J Elliott, J Vingerhoets, et al.
Pageof 3